Comparative proteomic profiling of triple-negative breast cancer reveals that up-regulation of RhoGDI-2 is associated to the inhibition of caspase 3 and caspase 9

Journal of Proteomics

Volumn 111, Issue , 2014, Pages 198-211

  Muñiz Lino, Marcos A ^a   Palacios Rodríguez, Yadira ^a   Rodríguez Cuevas, Sergio ^b   Bautista Piña, Verónica ^b   Marchat, Laurence A ^c   Ruíz García, Erika ^d   Astudillo de la Vega, Horacio ^e   González Santiago, Ana E ^a   Flores Pérez, Ali ^a   Díaz Chávez, José ^d   Carlos Reyes, Ángeles ^f   Álvarez Sánchez, Elizbeth ^a   López Camarillo, César ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b Institute of Breast Diseases FUCAM   (Mexico)

^c INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e HOSPITAL DE ONCOLOGÍA   (Mexico)

^f INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

Apoptosis; Caspases activation; Mitochondrial dysfunction; Proteomic profiling; RhoGDI 2; Triple negative breast cancer

Indexed keywords

ACYL COA BINDING PROTEIN ISOFORM 1; CASPASE 3; CASPASE 9; CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE SUBUNIT 5A; DIAZEPAM BINDING INHIBITOR; DJ 1 PROTEIN; DOXORUBICIN; FERRITIN LIGHT SUBUNIT; HEAT SHOCK PROTEIN 27; INITIATION FACTOR 5A; INITIATION FACTOR 5A 1; MYOTROPHIN PROTEIN; PROTEASOME ACTIVATOR COMPLEX SUBUNIT 1 ISOFORM 1; PROTEIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; SH3 DOMAIN BINDING GLUTAMIC ACID RICH LIKE PROTEIN; UBIQUITIN CONJUGATING ENZYME E2; UBIQUITIN CONJUGATING ENZYME E2 N; UNCLASSIFIED DRUG; CASP3 PROTEIN, HUMAN; CASP9 PROTEIN, HUMAN; CASPASE INHIBITOR; PEPTIDE; PROTEOME;

ADULT; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BREAST; BREAST CANCER CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEOMICS; RNA INTERFERENCE; SENSITIZATION; TANDEM MASS SPECTROMETRY; TRIPLE NEGATIVE BREAST CANCER; TWO DIMENSIONAL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING; BREAST NEOPLASMS; CHEMISTRY; COMPARATIVE STUDY; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; HELA CELL LINE; MASS SPECTROMETRY; MCF 7 CELL LINE; METABOLISM; METASTASIS; MIDDLE AGED; MITOCHONDRION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ADULT; APOPTOSIS; BREAST NEOPLASMS; CASPASE 3; CASPASE 9; CASPASE INHIBITORS; CELL LINE, TUMOR; CISPLATIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HUMANS; MASS SPECTROMETRY; MCF-7 CELLS; MIDDLE AGED; MITOCHONDRIA; NEOPLASM METASTASIS; PEPTIDES; PROTEOME; PROTEOMICS; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR BETA; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84910025367     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.04.019     Document Type: Article

References (56)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Bosch A., Eroles P., Zaragoza R., Viña J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010, 36(3):206-215.
3. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8(3):235-244.
4. Carey L., Winer E., Viale G., Cameron D., Gianni L. Triple-negative breast cancer: disease entity or title of convenience?. Nat Rev Clin Oncol 2010, 7(12):683-692.
5. Schulz D.M., Böllner C., Thomas G., Atkinson M., Esposito I., Höfler H., et al. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J Proteome Res 2009, 8(7):3430-3438.
6. Cabezón T., Gromova I., Gromov P., Serizawa R., Timmermans Wielenga V., Kroman N., et al. Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics 2013, 12(2):381-394.
7. Gámez-Pozo A., Ferrer N.I., Ciruelos E., López-Vacas R., Martínez F.G., Espinosa E., et al. Shotgun proteomics of archival triple-negative breast cancer samples. Proteomics Clin Appl 2013, 7(3-4):283-291.
8. Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M. Proteomic portrait of human breast cancer progression identifies novel prognostic markers. Cancer Res 2012, 72(9):2428-2439.
9. Garcia-Mata R., Boulter E., Burridge K. The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol 2011, 12(8):493-504.
10. Moon S.Y., Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 2003, 13:13-22.
11. Dovas A., Couchman J.R. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 2005, 390(1):1-9.
12. Gildea J.J., Seraj M.J., Oxford G., Harding M.A., Hampton G.M., Moskaluk C.A., et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002, 62(22):6418-6423.
13. Titus B., Frierson H.F., Conaway M., Ching K., Guise T., Chirgwin J., et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005, 65(16):7320-7327.
14. Wu Y., McRoberts K., Berr S.S., Frierson H.F., Conaway M., Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007, 26(5):765-773.
15. Jiang W.G., Watkins G., Lane J., Cunnick G.H., Douglas-Jones A., Mokbel K., et al. Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 2003, 9(17):6432-6440.
16. Moon H.G., Jeong S.H., Ju Y.T., Jeong C.Y., Lee J.S., Lee Y.J., et al. Up-regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat 2010, 42(3):151-156.
17. Zhang Y., Zhang B. D4-GDI, a Rho GTPase regulator, promotes breast cancer cell invasiveness. Cancer Res 2006, 66(11):5592-5598.
18. Zhang Y., Rivera Rosado L.A., Moon S.Y., Zhang B. Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling. J Biol Chem 2009, 284(19):12956-12965.
19. Hu L.D., Zou H.F., Zhan S.X., Cao K.M. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Rep 2007, 17(6):1383-1389.
20. Rivera Rosado L.A., Rodriguez-Canales J., Zhang B. Association of D4-GDI expression with breast cancer progression. Cancer Biomark 2011, 10(3-4):163-173.
21. Harding M.A., Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urol Oncol 2007, 25(5):401-406.
22. Harding M.A., Theodorescu D. RhoGDI signaling provides targets for cancer therapy. Eur J Cancer 2010, 46(7):1252-1259.
23. Zhang B. Rho GDP dissociation inhibitors as potential targets for anticancer treatment. Drug Resist Updat 2006, 9(3):134-141.
24. Na S., Chuang T.H., Cunningham A., Turi T.G., Hanke J.H., Bokoch G.M., et al. D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis. J Biol Chem 1996, 271(19):11209-11213.
25. Kwon K.B., Park E.K., Ryu D.G., Park B.H. D4-GDI is cleaved by caspase-3 during daunorubicin-induced apoptosis in HL-60 cells. Exp Mol Med 2005, 34(1):32-37.
26. Choi M.R., Groot M., Drexler H.C. Functional implications of caspase-mediated RhoGDI2 processing during apoptosis of HL60 and K562 leukemia cells. Apoptosis 2007, 12(11):2025-2035.
27. Fonseca-Sánchez M.A., Rodríguez-Cuevas S., Mendoza-Hernández G., Bautista-Piña V., Arechaga Ocampo E., Hidalgo Miranda A., et al. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int J Oncol 2012, 41(2):670-680.
28. Díaz-Chávez J., Fonseca-Sánchez M.A., Arechaga-Ocampo E., Flores-Pérez A., Palacios-Rodríguez Y., Domínguez-Gómez G., et al. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLOS One 2014, (in press).
29. Stevens E.V., Banet N., Onesto C., Plachco A., Alan J.K., Nikolaishvili-Feinberg N., et al. RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis. Small GTPases 2011, 2(4):202-210.
30. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299(5604):256-259.
31. Zhu X.L., Wang Z.F., Lei W.B., Zhuang H.W., Jiang H.Y., Wen W.P. DJ-1. A novel independent prognostic marker for survival in glottic squamous cell carcinoma. Cancer Sci 2012, 101(5):1320-1325.
32. Yuen H.F., Chan Y.P., Law S., Srivastava G., El-Tanani M., Mak T.W., et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3593-3602.
33. De Palma G., Mozzoni P., Acampa O., Internullo E., Carbognani P., Rusca M., et al. Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer. J Nucleic Acids 2010, 2010. [ID 147528].
34. Mannello F., Tonti G.A., Pederzoli A., Simone P., Smaniotto A., Medda V. Detection of superoxide dismutase-1 in nipple aspirate fluids: a reactive oxygen species-regulating enzyme in the breast cancer microenvironment. Clin Breast Cancer 2010, 10(3):238-245.
35. Somwar R., Erdjument-Bromage H., Larsson E., Shum D., Lockwood W.W., Yang G., et al. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines. Proc Natl Acad Sci U S A 2001, 108(39):16375-16380.
36. Rao A.K., Ziegler Y.S., McLeod I.X., Yates J.R., Nardulli A.M. Effects of Cu/Zn superoxide dismutase on estrogen responsiveness and oxidative stress in human breast cancer cells. Mol Endocrinol 2008, 22(5):1113-1124.
37. Kim J.W., Sahm H., You J., Wang M. Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells. Anticancer Res 2010, 30(7):2577-2581.
38. Brown D.P., Chin-Sinex H., Nie B., Mendonca M.S., Wang M. Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer. Cancer Chemother Pharmacol 2009, 63(4):723-730.
39. Liu L., Chen R., Huang S., Wu Y., Li G., Liu Q., et al. Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy. Med Oncol 2011, 28(3):835-839.
40. Park M.H., Wolff E.C., Folk J.E. Hypusine: its post-translational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. Biofactors 1993, 4(2):95-104.
41. Caraglia M., Park M.H., Wolff E.C., Marra M., Abbruzzese A. eIF5A isoforms and cancer: two brothers for two functions?. Amino Acids 2013, 44(1):103-109.
42. Moghanibashi M., Rastgar Jazii F., Soheili Z.S., Zare M., Karkhane A., Parivar K., et al. Esophageal cancer alters the expression of nuclear pore complex binding protein Hsc70 and eIF5A-1. Funct Integr Genomics 2013, 13(2):253-260.
43. Lam F., Jankova L., Dent O.F., Molloy M.P., Kwun S.Y., Clarke C., et al. Identification of distinctive protein expression patterns in colorectal adenoma. Proteomics Clin Appl 2010, 4(1):60-70.
44. Cracchiolo B.M., Heller D.S., Clement P.M., Wolff E.C., Park M.H., Hanauske-Abel H.M. Eukaryotic initiation factor 5A-1 (eIF5A-1) as a diagnostic marker for aberrant proliferation in intraepithelial neoplasia of the vulva. Gynecol Oncol 2004, 94(1):217-222.
45. Garrido C., Brunet M., Didelot C., Zermati Y., Schmitt E., Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006, 5(22):2592-2601.
46. Rocchi P.A., So A., Kojima S., Signaevsky M., Beraldi E., Fazli L., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64(18):6595-6602.
47. Oesterreich S., Weng C.N., Qiu M., Hilsenbeck S.G., Osborne C.K., Fuqua S.A. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 1993, 53(19):4443-4448.
48. Morii T., Ohtsuka K., Ohnishi H., Mochizuki K., Satomi K. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Res 2010, 30(9):3565-3571.
49. Sõti C., Nagy E., Giricz Z., Vígh L., Csermely P., Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005, 146(6):769-780.
50. Schultz C.R., Golembieski W.A., King D.A., Brown S.L., Brodie C., Rempel S.A. Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer 2012, 11:20.
51. Pulvino M., Liang Y., Oleksyn D., DeRan M., Van Pelt E., Shapiro J., et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood 2012, 120(8):1668-1677.
52. Longuespée R., Boyon C., Castellier C., Jacquet A., Desmons A., Kerdraon O., et al. The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling. Histochem Cell Biol 2012, 138(1):141-154.
53. Wang Z., Feng X., Liu X., Jiang L., Zeng X., Ji N., et al. Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis. BMC Genomics 2009, 10:383.
54. Zhang D., Lim S.G., Koay E.S. Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma. Int J Oncol 2007, 31(3):577-584.
55. Majid S.M., Liss A.S., You M., Bose H.R. The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene 2006, 25(5):756-768.
56. Brand M.D., Nicholls D.G. Assessing mitochondrial dysfunction in cells. Biochem J 2011, 435(2):297-312.